MCID: PLS007
MIFTS: 54

Plasmodium Falciparum Malaria

Categories: Infectious diseases

Aliases & Classifications for Plasmodium Falciparum Malaria

MalaCards integrated aliases for Plasmodium Falciparum Malaria:

Name: Plasmodium Falciparum Malaria 12 14
Malaria, Falciparum 42 69
Plasmodium Falciparum Malaria, Unspecified 12
Falciparum Malaria [malignant Tertian] 12
Malaria Fever, Subtertian 12
Malignant Tertian Fever 12
Falciparum Malaria 12
Malaria Falciparum 52

Classifications:



External Ids:

Disease Ontology 12 DOID:14067
ICD10 33 B50 B50.9 B50.0
ICD9CM 35 084.0
MeSH 42 D016778
NCIt 47 C34798
UMLS 69 C0024535

Summaries for Plasmodium Falciparum Malaria

Disease Ontology : 12 A malaria described as a severe form of the disease caused by a parasite Plasmodium falciparum, which is marked by irrregular recurrence of paroxysms and prolonged or continuous fever.

MalaCards based summary : Plasmodium Falciparum Malaria, also known as malaria, falciparum, is related to lymphoma and asthma. An important gene associated with Plasmodium Falciparum Malaria is CR1 (Complement C3b/C4b Receptor 1 (Knops Blood Group)), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Amodiaquine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and liver, and related phenotypes are hematopoietic system and cellular

Related Diseases for Plasmodium Falciparum Malaria

Diseases related to Plasmodium Falciparum Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
id Related Disease Score Top Affiliating Genes
1 lymphoma 30.1 IFNG IL10 TLR9 TNF
2 asthma 28.3 ICAM1 IFNG IL10 IL18 SELE TLR9
3 malaria 25.3 CD36 CD55 CHIT1 CR1 DHFR FCGR2A
4 hemolytic anemia due to g6pd deficiency 11.2
5 pure autonomic failure 10.9 IL10 TNF
6 acute ackee fruit intoxication 10.8 IL10 TNF
7 eye accommodation disease 10.8 IFNG IL10
8 sternal cleft 10.7 IFNG TNF
9 multiple familial trichoepithelioma 10.7 IL10 TNF
10 tabatznik syndrome 10.7 IL18 TNF
11 plantar wart 10.7 IFNG IL10 TNF
12 oropharyngeal cancer, childhood 10.7 IFNG IL10 TNF
13 autoimmune polyglandular syndrome type 3 10.7 IFNG TNF
14 cyclosporiasis 10.7 IFNG IL10 TNF
15 early-onset zonular cataract 10.7 IFNG IL10 TNF
16 hepadnavirus infection 10.7 IFNG IL10 TNF
17 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.7 CD36 IFNG IL10
18 senile reticular retinal degeneration 10.6 IFNG IL10 TNF
19 psychologic dyspareunia 10.6 IFNG IL10 TNF
20 hemophagocytic lymphohistiocytosis 10.6 IFNG IL10 TNF
21 basidiobolomycosis 10.6 IL10 TNF
22 bartonellosis 10.6 IFNG IL10 TNF
23 lagophthalmos 10.6 IL10 TNF
24 orbital osteomyelitis 10.6 IFNG IL10 TNF
25 disease of mental health 10.6 IFNG IL10 TNF
26 abnormal retinal correspondence 10.6 IFNG IL10 TNF
27 extrahepatic bile duct adenocarcinoma 10.6 IFNG IL10 TNF
28 cornea cancer 10.6 IFNG IL10 TNF
29 left bundle branch hemiblock 10.6 IFNG IL10 TNF
30 ovarian endometrioid cystadenoma 10.6 CD55 HP IL10
31 burn scar 10.6 IFNG IL10 TNF
32 steatorrhea 10.6 IFNG IL18 TNF
33 atrichia with papular lesions 10.6 ICAM1 IFNG TNF
34 reardon wilson cavanagh syndrome 10.6 IFNG IL18 TNF
35 bolivian hemorrhagic fever 10.6 ICAM1 IFNG TNF
36 hemorrhagic fever 10.6 HBB HP
37 proximal symphalangism 10.6 ICAM1 IL10 TNF
38 blue toe syndrome 10.5 IFNG IL10 TNF
39 louping ill 10.5 ICAM1 IFNG TNF
40 pyelonephritis 10.5 ICAM1 IL10 TNF
41 keratomalacia 10.5 IFNG IL10 TNF
42 erythema infectiosum 10.5 IFNG IL18 TNF
43 uterus interstitial leiomyoma 10.5 IFNG IL10 TNF
44 alopecia 10.5 ICAM1 IL10 TNF
45 vulvar nodular hidradenoma 10.5 IFNG IL10 IL18
46 respiratory system disease 10.5 IFNG IL10 TNF
47 acral lentiginous melanoma 10.5 IFNG IL10 TNF
48 intestinal disaccharidase deficiency 10.5 ICAM1 IFNG TNF
49 moderately severe hemophilia b 10.5 FCGR2A IL10 TNF
50 neonatal stroke 10.5 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Plasmodium Falciparum Malaria:



Diseases related to Plasmodium Falciparum Malaria

Symptoms & Phenotypes for Plasmodium Falciparum Malaria

MGI Mouse Phenotypes related to Plasmodium Falciparum Malaria:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 CD36 CD55 FCGR2A G6PD HP ICAM1
2 cellular MP:0005384 10.23 CD36 G6PD HP ICAM1 IFNG IL10
3 cardiovascular system MP:0005385 10.18 CD36 G6PD HP ICAM1 IFNG IL10
4 homeostasis/metabolism MP:0005376 10.15 MIF SELE TLR9 TNF CD36 G6PD
5 immune system MP:0005387 10.1 IFNG IL10 IL18 MIF SELE TLR9
6 digestive/alimentary MP:0005381 9.98 CD36 ICAM1 IFNG IL10 IL18 TLR9
7 mortality/aging MP:0010768 9.97 CD36 DHFR FCGR2A G6PD HP ICAM1
8 liver/biliary system MP:0005370 9.73 CD36 HP IFNG IL10 SELE TNF
9 muscle MP:0005369 9.5 TNF CD36 ICAM1 IFNG IL10 IL18
10 neoplasm MP:0002006 9.1 HP ICAM1 IFNG IL10 MIF TNF

Drugs & Therapeutics for Plasmodium Falciparum Malaria

Drugs for Plasmodium Falciparum Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 228)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amodiaquine Approved Phase 4,Phase 3,Phase 2,Phase 1 86-42-0 2165
2
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1 71963-77-4 119380 68911
3
Artesunate Approved Phase 4,Phase 3,Phase 2,Phase 1 88495-63-0 6917864 5464098
4
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1 82186-77-4 6437380
5
Mefloquine Approved Phase 4,Phase 2,Phase 3,Phase 1 53230-10-7 4046
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
7
chloroquine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-05-7 2719
8
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-34-6 4908
9
Pyrimethamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 58-14-0 4993
10
Sulfadoxine Approved Phase 4,Phase 3,Phase 2,Phase 1 2447-57-6 17134
11
Azithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 83905-01-5 55185 53477736 447043
12
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
13
Quinine Approved Phase 4,Phase 3,Phase 2 130-95-0 8549 3034034
14
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2 723-46-6 5329
15
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 738-70-5 5578
16
Nevirapine Approved Phase 4,Phase 1,Phase 2,Early Phase 1 129618-40-2 4463
17
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80-08-0 2955
18
Proguanil Approved Phase 4,Phase 2,Phase 3,Phase 1 500-92-5 4923
19
Atovaquone Approved Phase 4,Phase 2,Phase 3,Phase 1 95233-18-4 74989
20
Morphine Approved, Investigational Phase 4 57-27-2 5288826
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
22
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
23
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
24
Pyronaridine Investigational Phase 4,Phase 3,Phase 2,Phase 1 74847-35-1 5485198
25
Chlorproguanil Investigational Phase 4,Phase 3,Phase 2,Phase 1 537-21-3 151170 9571037
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Artemether-lumefantrine combination Phase 4,Phase 3,Phase 2,Phase 1
31 Artemisinine Phase 4,Phase 3,Phase 2,Phase 1
32 Artemisinins Phase 4,Phase 3,Phase 2,Phase 1
33
Dihydroartemisinin Phase 4,Phase 3,Phase 2,Phase 1 71939-50-9 6918483
34
Piperaquine Phase 4,Phase 3,Phase 2,Phase 1 4085-31-8 5079497
35 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1
36 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Amodiaquine, artesunate drug combination Phase 4
38 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
39 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
42 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Chloroquine diphosphate Phase 4,Phase 3,Phase 2,Phase 1 50-63-5
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Fanasil, pyrimethamine drug combination Phase 4,Phase 3,Phase 2,Phase 1
46 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
49 Antipyretics Phase 4,Phase 3
50 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 510)

id Name Status NCT ID Phase Drugs
1 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
2 P. Falciparum Resistance to Artemisinin in Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
3 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Unknown status NCT01930331 Phase 4 artemisinin/naphthoquine;dihydroartemisinin/piperaquine phosphate
4 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
5 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
6 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
7 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4 Artesunate;Mefloquine
8 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
9 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
10 Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania Unknown status NCT02199951 Phase 4 Dihydroartemisinin and piperaquine
11 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
12 Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal Unknown status NCT00712374 Phase 4 sulfadoxine-pyrimethamine plus amodiaquine
13 A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women Unknown status NCT02575755 Phase 4 Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
14 Impact of Insecticide Resistance on Vector Control Unknown status NCT01713517 Phase 4
15 The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau Unknown status NCT00137566 Phase 4 acetaminophen (paracetamol)
16 Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia Completed NCT02325180 Phase 4 Dihydroartemisinin-Piperaquine;Artemether-lumefantrine
17 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
18 Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. Completed NCT02089841 Phase 4 Artemether-lumefantrine
19 Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00540410 Phase 4 Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination);Coartem® (arthemether+ lumefantrine)
20 Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria Completed NCT00529867 Phase 4 Artemether/lumefantrine tablets;Artemether/Lumefantrine suspension
21 Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania Completed NCT00885287 Phase 4 Artemether-lumefantrine (AL)
22 Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00699920 Phase 4 Coarsucam;Coartem
23 Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso Completed NCT01017770 Phase 4 Artesunate-amodiaquine;Artemether-lumefantrine
24 Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria Completed NCT00978172 Phase 4 artesunate and mefloquine
25 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
26 Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria Completed NCT00425763 Phase 4 AQAS
27 Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger Completed NCT01755559 Phase 4 Artesunate-amodiaquine;Dihydroartemisinin-piperaquine;Artemether-lumefantrine
28 Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi Completed NCT00164359 Phase 4 Amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate
29 Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan Completed NCT01019408 Phase 4 Chloroquine
30 CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi Completed NCT00125489 Phase 4 chloroquine sulfate;sulfadoxine/pyrimethamine
31 The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia Completed NCT02297477 Phase 4 atovaquone-proguanil;artesunate-atovaquone-proguanil
32 Tracking Resistance to Artemisinin (TRAC) Completed NCT01350856 Phase 4 Artesunate 2;Artesunate 4
33 Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area Completed NCT00935688 Phase 4
34 Kintampo Trial of Combination Therapy for Malaria Completed NCT00119145 Phase 4 artesunate-amodiaquine;coartem;artesunate-lapdap
35 Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru Completed NCT00164216 Phase 4 mefloquine plus artesunate
36 Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers Completed NCT00233337 Phase 4 Co-artemether
37 Harmonized AS/MQ Efficacy Study - Thailand Completed NCT02052323 Phase 4 Artesunate/mefloquine (AS/MQ)
38 Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine Completed NCT00167739 Phase 4 Quinine plus sulfadoxine-pyrimethamine
39 Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function Completed NCT00444106 Phase 4 Artesunate-mefloquine;Atovaquone-proguanil;Artemether-lumefantrine
40 Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire Completed NCT01023399 Phase 4 Artesunate + Amodiaquine
41 Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance Completed NCT00445796 Phase 4 Artesunate;Amodiaquine
42 Plasmodium Falciparum Artemisinin Resistance Vietnam Completed NCT01775592 Phase 4 Arterakin (DHA-PPQ)
43 A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects Completed NCT00859807 Phase 4 Flavoquine®, Camoquin® Suspension;Flavoquine®, Camoquin® Suspension
44 Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar Completed NCT00549003 Phase 4
45 Amodiaquine+Artesunate for Uncomplicated Malaria Treatment Completed NCT01213433 Phase 4 Artesunate-Amodiaquine
46 Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy Completed NCT00495508 Phase 4 Quinine;artemether / lumefantrine
47 Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine Completed NCT01998295 Phase 4 Artemether/lumefantrine
48 Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo Completed NCT02741024 Phase 4 Amodiaquine-Artesunate (ASAQ);Artemether-Lumefantrine (AL)
49 Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria Completed NCT02092766 Phase 4 artesunate;quinine
50 Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso Completed NCT01697787 Phase 4 Amodiaquine-Artesunate;Artemether-lumefantrine

Search NIH Clinical Center for Plasmodium Falciparum Malaria

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: malaria, falciparum

Genetic Tests for Plasmodium Falciparum Malaria

Anatomical Context for Plasmodium Falciparum Malaria

MalaCards organs/tissues related to Plasmodium Falciparum Malaria:

39
Testes, T Cells, Liver, Skin, Neutrophil, Bone, Endothelial

Publications for Plasmodium Falciparum Malaria

Articles related to Plasmodium Falciparum Malaria:

(show top 50) (show all 733)
id Title Authors Year
1
Congenital Plasmodium falciparum Malaria in Washington, DC. ( 28077745 )
2017
2
Age and geographic patterns of Plasmodium falciparum malaria infection in a representative sample of children living in Burkitt lymphoma-endemic areas of northern Uganda. ( 28320389 )
2017
3
Therapeutic plasma exchange in the treatment of complicated Plasmodium falciparum malaria: A case report. ( 28922459 )
2017
4
Sustained High Cure Rate of Artemether-Lumefantrine against Uncomplicated Plasmodium falciparum Malaria after 8 Years of Its Wide-Scale Use in Bagamoyo District, Tanzania. ( 28829723 )
2017
5
Association of CD40L gene polymorphism with severe Plasmodium falciparum malaria in Indian population. ( 28352049 )
2017
6
Expression of cleaved caspase-3 in renal tubular cells in Plasmodium falciparum malaria patients. ( 26729581 )
2017
7
Combating multidrug-resistant Plasmodium falciparum malaria. ( 28580606 )
2017
8
Performance of a High-Sensitivity Rapid Diagnostic Test for Plasmodium falciparum Malaria in Asymptomatic Individuals from Uganda and Myanmar and Naive Human Challenge Infections. ( 28820709 )
2017
9
Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis. ( 28028628 )
2017
10
Pulmonary manifestation of Plasmodium falciparum malaria: Case reports and review of the literature. ( 28702342 )
2017
11
AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. ( 28916443 )
2017
12
The oxylipin and endocannabidome responses in acute phase Plasmodium falciparum malaria in children. ( 28886714 )
2017
13
Obesity and Diabetes as Risk Factors for Severe Plasmodium falciparum Malaria: Results From a Swedish Nationwide Study. ( 28510633 )
2017
14
Plasmodium falciparum malaria parasite var gene expression is modified by host antibodies: longitudinal evidence from controlled infections of Kenyan adults with varying natural exposure. ( 28835215 )
2017
15
Multicenter Pivotal Clinical Trial of Urine Malaria Test for Rapid Diagnosis of Plasmodium falciparum Malaria. ( 27847373 )
2017
16
Comparative study of clinical presentation and hematological indices in hospitalized sickle cell patients with severe Plasmodium falciparum malaria. ( 28927555 )
2017
17
Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. ( 28605472 )
2017
18
Elimination of Plasmodium falciparum malaria in Tajikistan. ( 28558764 )
2017
19
Plasmodium falciparum malaria co-infection with tick-borne relapsing fever in Dakar. ( 28077149 )
2017
20
Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in CA'te d'Ivoire. ( 28049523 )
2017
21
Analysis of the Clinical Profile in Patients with Plasmodium falciparum Malaria and Its Association with Parasite Density. ( 28584457 )
2017
22
Effects of Aging on Parasite Biomass, Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Plasmodium knowlesi and Plasmodium falciparum Malaria. ( 28863470 )
2017
23
Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa. ( 28785011 )
2017
24
High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series. ( 27986683 )
2017
25
Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. ( 28454557 )
2017
26
Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. ( 28566213 )
2017
27
K13-propeller Alleles, Mdr1 Polymorphism, and Drug Effectiveness at Day 3 after Artemether-lumefantrine Treatment for Plasmodium falciparum Malaria in Colombia, 2014-2015. ( 28947476 )
2017
28
Severe Plasmodium falciparum malaria in the intensive care unit: A 6-year experience in Milano, Italy. ( 28554853 )
2017
29
Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria. ( 28722611 )
2017
30
Evidence of non-Plasmodium falciparum malaria infection in KAcdougou, SAcnAcgal. ( 28049489 )
2017
31
Severe unresolving Plasmodium falciparum malaria following artemisinin combination therapy: Emergence of drug resistance in Saudi Arabia. ( 27934844 )
2016
32
Quantitative, model-based estimates of variability in the generation and serial intervals of Plasmodium falciparum malaria. ( 27660051 )
2016
33
Efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in western Cambodia. ( 26926629 )
2016
34
K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar. ( 26911145 )
2016
35
Effect of Plasmodium falciparum malaria parasites on haematological parameters in Ghanaian children. ( 27413299 )
2016
36
Placental Sequestration of Plasmodium falciparum Malaria Parasites Is Mediated by the Interaction Between VAR2CSA and Chondroitin Sulfate A on Syndecan-1. ( 27556547 )
2016
37
Anemia, Iron Supplementation and Susceptibility to Plasmodium falciparum Malaria. ( 27919755 )
2016
38
Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. ( 26906747 )
2016
39
TRALI Syndrome During the Treatment of a Plasmodium falciparum Malaria Case. ( 28091389 )
2016
40
Adding a single low-dose of primaquine (0.25A mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial. ( 27565897 )
2016
41
A common TLR1 polymorphism is associated with higher parasitaemia in a Southeast Asian population with Plasmodium falciparum malaria. ( 26738805 )
2016
42
Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. ( 27430374 )
2016
43
Open-label trial on efficacy of artemether/lumefantrine against the uncomplicated Plasmodium falciparum malaria in Metema district, Northwestern Ethiopia. ( 27601913 )
2016
44
Plasmodium falciparum malaria in 1(st)-2(nd) century CE southern Italy. ( 27923126 )
2016
45
Is a reproduction number of one a threshold for Plasmodium falciparum malaria elimination? ( 27456218 )
2016
46
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction. ( 26917051 )
2016
47
Determination of PCT on admission is a useful tool for the assessment of disease severity in travelers with imported Plasmodium falciparum malaria. ( 27078668 )
2016
48
Artemisinin-Based Combination Therapy Versus Quinine or Other Combinations for Treatment of Uncomplicated Plasmodium falciparum Malaria in the Second and Third Trimester of Pregnancy: A Systematic Review and Meta-Analysis. ( 26788543 )
2016
49
Cord blood IgG and the risk of severe Plasmodium falciparum malaria in the first year of life. ( 27890694 )
2016
50
Parenteral Artesunate for Severe Imported Plasmodium falciparum Malaria in Children. ( 27518753 )
2016

Variations for Plasmodium Falciparum Malaria

Expression for Plasmodium Falciparum Malaria

Search GEO for disease gene expression data for Plasmodium Falciparum Malaria.

Pathways for Plasmodium Falciparum Malaria

Pathways related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 34)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 CD36 CD55 CHIT1 CR1 FCGR2A HBB
2
Show member pathways
12.78 CD55 ICAM1 IFNG IL10 TNF
3
Show member pathways
12.73 ICAM1 IFNG IL18 TLR9 TNF
4
Show member pathways
12.18 CR1 FCGR2A IFNG IL10 TNF
5
Show member pathways
12.11 IFNG IL10 IL18 TNF
6 12.06 ICAM1 IFNG SELE TNF
7 12.05 CR1 FCGR2A IFNG IL10 IL18 TLR9
8 11.95 FCGR2A ICAM1 IFNG MIF TNF
9 11.92 CD36 FCGR2A IFNG IL10 TNF
10 11.89 CD36 ICAM1 IL10 IL18 TNF
11
Show member pathways
11.86 CD36 HBB HP
12 11.85 CD36 CD55 CR1 TNF
13 11.83 ICAM1 SELE TNF
14 11.81 IFNG IL10 TNF
15 11.81 ICAM1 IFNG IL18 TNF
16
Show member pathways
11.8 IFNG IL10 IL18 TLR9 TNF
17 11.76 CR1 FCGR2A TLR9
18 11.75 IFNG IL10 IL18 TNF
19 11.74 ICAM1 IFNG SELE
20 11.72 IFNG IL10 TLR9 TNF
21 11.56 FCGR2A ICAM1 IL10
22 11.54 CR1 IL18 TNF
23 11.54 CD36 CR1 FCGR2A ICAM1 IL10 TLR9
24
Show member pathways
11.52 ICAM1 IFNG MIF SELE TNF
25 11.49 ICAM1 IL10 IL18 TNF
26 11.48 HP ICAM1 TNF
27 11.47 IFNG IL18 TNF
28
Show member pathways
11.38 IFNG IL10 TNF
29 11.34 CD36 CR1 HBB ICAM1 IFNG IL10
30 11.27 IFNG IL18 TNF
31 11.24 IFNG IL10 TNF
32 11.15 ICAM1 IFNG IL18
33 10.9 CD36 ICAM1 TNF
34 10.77 HBB ICAM1 IFNG IL10 IL18 SELE

GO Terms for Plasmodium Falciparum Malaria

Cellular components related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CD55 CHIT1 HBB HP IFNG IL10
2 external side of plasma membrane GO:0009897 9.73 CD36 ICAM1 IFNG TNF
3 cell surface GO:0009986 9.73 CD36 CD55 CR1 ICAM1 MIF TNF
4 secretory granule membrane GO:0030667 9.63 CD55 CR1 FCGR2A
5 tertiary granule lumen GO:1904724 9.54 CHIT1 HBB HP
6 extracellular space GO:0005615 9.4 CD36 CHIT1 HBB HP ICAM1 IFNG
7 membrane raft GO:0045121 9.35 CD36 CD55 ICAM1 SELE TNF
8 haptoglobin-hemoglobin complex GO:0031838 9.32 HBB HP
9 extracellular exosome GO:0070062 10.1 CD55 CR1 FCGR2A G6PD HBB HP

Biological processes related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 40)
id Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.96 ICAM1 MIF SELE TNF
2 negative regulation of gene expression GO:0010629 9.94 CD36 IFNG MIF TNF
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 CD36 ICAM1 MIF TNF
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 CD36 ICAM1 MIF
5 viral entry into host cell GO:0046718 9.85 CD55 CR1 ICAM1
6 inflammatory response GO:0006954 9.85 IL10 IL18 MIF SELE TLR9 TNF
7 response to hydrogen peroxide GO:0042542 9.8 HBB HP MB
8 defense response to bacterium GO:0042742 9.8 HP IFNG IL10 TLR9 TNF
9 positive regulation of gene expression GO:0010628 9.77 IFNG TLR9 TNF
10 positive regulation of interleukin-6 production GO:0032755 9.76 CD36 TLR9 TNF
11 neutrophil degranulation GO:0043312 9.76 CD36 CD55 CHIT1 CR1 FCGR2A HBB
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.74 ICAM1 TLR9 TNF
13 positive regulation of cytokine secretion GO:0050715 9.71 IL10 MIF TNF
14 negative regulation of interleukin-6 production GO:0032715 9.69 IL10 TLR9 TNF
15 leukocyte tethering or rolling GO:0050901 9.68 SELE TNF
16 oxygen transport GO:0015671 9.68 HBB MB
17 response to molecule of bacterial origin GO:0002237 9.68 IL10 TLR9
18 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
19 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.66 IL18 TLR9
20 positive regulation of chemokine biosynthetic process GO:0045080 9.66 IFNG TNF
21 endothelial cell apoptotic process GO:0072577 9.65 IL10 TNF
22 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IFNG IL10
23 cellular response to lipopolysaccharide GO:0071222 9.65 CD36 ICAM1 IFNG IL10 TNF
24 regulation of removal of superoxide radicals GO:2000121 9.64 CD36 DHFR
25 positive regulation of interleukin-12 production GO:0032735 9.63 CD36 IFNG TLR9
26 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.62 ICAM1 TNF
27 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 IL10 TNF
28 type 2 immune response GO:0042092 9.61 IL10 IL18
29 negative regulation of interleukin-8 production GO:0032717 9.61 IL10 TLR9
30 positive regulation of NF-kappaB import into nucleus GO:0042346 9.61 IL18 TLR9 TNF
31 positive regulation of cell death GO:0010942 9.6 HBB HP
32 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.58 MIF TNF
33 receptor biosynthetic process GO:0032800 9.56 IL10 TNF
34 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.55 IFNG TNF
35 positive regulation of tumor necrosis factor production GO:0032760 9.5 CD36 IFNG TLR9
36 positive regulation of vitamin D biosynthetic process GO:0060557 9.49 IFNG TNF
37 positive regulation of blood microparticle formation GO:2000334 9.48 CD36 TNF
38 negative regulation of growth of symbiont in host GO:0044130 9.26 CD36 IFNG IL10 TNF
39 positive regulation of nitric oxide biosynthetic process GO:0045429 8.92 HBB ICAM1 IFNG TNF
40 immune response GO:0006955 10 CD36 CHIT1 IFNG IL10 IL18 TNF

Molecular functions related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.33 CD55 CR1 ICAM1
2 oxygen transporter activity GO:0005344 9.26 HBB MB
3 cytokine activity GO:0005125 9.02 IFNG IL10 IL18 MIF TNF
4 hemoglobin binding GO:0030492 8.96 HBB HP

Sources for Plasmodium Falciparum Malaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....